Peripheral arterial disease
Conditions
Interventions
None listed
Sponsors
Universiteit Twente
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Male or female > 18 years of age - Stenotic lesion in the SFA treated with a BioMimic 3D stent - Willingness to visit the hospital and undergo HFR-CEUS measurements and a CTA scan - Signed informed consent
Exclusion criteria
Exclusion criteria: - Hypersensitivity to the active substance(s) or any of the excipients in SonoVue - Right-to-left cardiac shunt - Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg) - Uncontrolled systemic hypertension - Severe pulmonary disease (e.g. COPD GOLD 3/4, adult respiratory distress syndrome) - Clinically unstable cardiac disease (recent or ongoing myorcardial infarction, unstable angina at rest, recent percutaneous coronary intervention (PCI), clinically worsening cardiac symptoms, severe cardiac arrythmia*s, endocarditis, etc.) - Loss of renal function (GFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vector velocity fields derived from echoPIV data will be used to calculate and visualize spatiotemporal blood flow velocity profiles. Offline analysis will be used to investigate the existence of swirling flow patterns. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary study parameters are as follows: - The spatiotemporal swirling blood flow patterns obtained with echoPIV with the patient in supine position and in sitting position will be compared to investigate the influence of the patients* position on swirling blood flow patterns. - CTA images from the patients* upper leg will be used to assess the geometry of the treated vessel and its link to echoPIV outcomes in terms of swirling flow. - Velocity estimates obtained with conventional Doppler ultrasound will be compared to echoPIV outcomes. - Flow related parameters, indicating the presence of swirling flow, will be calculated. | — |
Countries
Netherlands
Outcome results
None listed